Meridian Bioscience Company Profile (NASDAQ:VIVO)

About Meridian Bioscience

Meridian Bioscience logoMeridian Bioscience, Inc. (Meridian) is an integrated life science company. The Company is engaged in developing, manufacturing, selling and distribution of clinical diagnostic test kits, for certain gastrointestinal, viral, respiratory and parasitic infectious diseases; the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/ quantitative polymerase chain reaction (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers, and the contract development and manufacture of proteins and other biologicals under cyclic guanosine monophosphate (cGMP) conditions for use by biopharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Company operates in two segments: Diagnostics and Life Science.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: VIVO
  • CUSIP: 58958410
Key Metrics:
  • Previous Close: $19.27
  • 50 Day Moving Average: $19.31
  • 200 Day Moving Average: $19.66
  • 52-Week Range: $16.86 - $21.49
  • Trailing P/E Ratio: 22.96
  • Foreward P/E Ratio: 21.43
  • P/E Growth: 1.40
  • Market Cap: $811.84M
  • Outstanding Shares: 42,086,000
  • Beta: 1.06
Profitability:
  • Net Margins: 17.95%
  • Return on Equity: 21.51%
  • Return on Assets: 16.40%
Debt:
  • Debt-to-Equity Ratio: 0.33%
  • Current Ratio: 6.27%
  • Quick Ratio: 4.13%
Additional Links:
Companies Related to Meridian Bioscience:

Analyst Ratings

Consensus Ratings for Meridian Bioscience (NASDAQ:VIVO) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $21.25 (10.16% upside)

Analysts' Ratings History for Meridian Bioscience (NASDAQ:VIVO)
Show:
DateFirmActionRatingPrice TargetDetails
8/1/2016Canaccord GenuityReiterated RatingHold$20.00View Rating Details
7/29/2016Hilliard LyonsDowngradeBuy -> HoldView Rating Details
3/29/2016Robert W. BairdReiterated RatingHold$20.00View Rating Details
1/27/2016William BlairReiterated RatingMarket PerformView Rating Details
11/6/2015Craig HallumBoost Price TargetBuy$21.00 -> $23.00View Rating Details
1/2/2015Raymond James Financial Inc.DowngradeMarket Perform -> UnderperformView Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Meridian Bioscience (NASDAQ:VIVO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/4/2016        
7/28/2016Q3$0.22$0.21$52.85 million$50.70 millionViewN/AView Earnings Details
4/28/2016Q2$0.24$0.24$52.10 million$51.30 millionViewN/AView Earnings Details
1/27/2016Q1$0.21$0.21$48.60 million$47.20 millionViewN/AView Earnings Details
11/5/2015Q4$0.21$0.20$45.70 million$47.10 millionViewN/AView Earnings Details
7/23/2015Q3$0.22$0.22$48.60 million$48.20 millionViewN/AView Earnings Details
4/23/2015Q115$0.24$0.24$50.50 million$51.55 millionViewN/AView Earnings Details
1/22/2015Q414$0.19$0.19$46.20 million$48.00 millionViewN/AView Earnings Details
11/6/2014Q4$0.22$0.20$48.94 million$46.70 millionViewN/AView Earnings Details
7/24/2014Q3$0.22$0.21$47.96 million$47.20 millionViewN/AView Earnings Details
4/24/2014Q214$0.27$0.24$52.18 million$50.13 millionViewN/AView Earnings Details
1/22/2014Q114$0.18$0.18$47.59 million$44.80 millionViewN/AView Earnings Details
11/7/2013Q313$0.23$0.22$49.24 million$48.96 millionViewN/AView Earnings Details
7/25/2013Q3 2013$0.21$0.24$47.00 million$47.10 millionViewN/AView Earnings Details
4/25/2013Q2 2013$0.24$0.24$49.66 million$47.26 millionViewN/AView Earnings Details
1/23/2013Q1 2013$0.19$0.20$44.34 million$45.40 millionViewN/AView Earnings Details
11/8/2012Q412$0.19$0.21$43.22 million$43.70 millionViewN/AView Earnings Details
7/26/2012$0.22$0.21ViewN/AView Earnings Details
4/26/2012$0.21$0.23ViewN/AView Earnings Details
1/25/2012$0.19$0.17ViewN/AView Earnings Details
11/10/2011$0.19$0.18ViewN/AView Earnings Details
7/21/2011$0.21$0.17ViewN/AView Earnings Details
4/21/2011$0.20$0.20ViewN/AView Earnings Details
1/20/2011$0.19$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Meridian Bioscience (NASDAQ:VIVO)
Current Year EPS Consensus Estimate: $0.86 EPS
Next Year EPS Consensus Estimate: $0.9 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162$0.24$0.25$0.25
Q2 20161$0.21$0.21$0.21
Q3 20161$0.20$0.20$0.20
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Meridian Bioscience (NASDAQ:VIVO)
Annual Dividend:$0.80
Dividend Yield:4.15%
Payout Ratio:96.39% (Based on Trailing 12 Months of Earnings)
93.02% (Based on Current Year Consensus EPS Estimate)
88.89% (Based on Next Year Consensus EPS Estimate)

Dividend History for Meridian Bioscience (NASDAQ:VIVO)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
7/28/2016quarterly$0.204.13%8/4/20168/8/20168/18/2016
4/28/2016quarterly$0.204.19%5/5/20165/9/20165/19/2016
1/27/2016quarterly$0.204.29%2/4/20162/8/20162/18/2016
11/5/2015quarterly$0.203.89%11/12/201511/16/201511/27/2015
7/23/2015quarterly$0.204.28%7/30/20158/3/20158/13/2015
4/23/2015quarterly$0.204.18%4/30/20155/4/20155/14/2015
1/22/2015quarterly$0.204.51%1/29/20152/2/20152/13/2015
11/6/2014quarterly$0.204.75%11/13/201411/17/201411/28/2014
7/24/2014quarterly$0.203.99%7/31/20148/4/20148/14/2014
4/24/2014quarterly$0.204.05%5/1/20145/5/20145/15/2014
1/22/2014quarterly$0.203.13%1/30/20142/3/20142/14/2014
11/7/2013quarterly$0.193.04%11/14/201311/18/201311/29/2013
7/25/2013quarterly$0.193.13%8/1/20138/5/20138/15/2013
4/25/2013quarterly$0.193.88%5/1/20135/4/20135/14/2013
12/4/2012quarterly$0.1912/14/201212/24/2012
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Meridian Bioscience (NASDAQ:VIVO)
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 88.03%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2016John McilwraithDirectorBuy1,000$19.57$19,570.00View SEC Filing  
4/29/2016Catherine SazdanoffDirectorBuy7,700$19.20$147,840.00View SEC Filing  
12/9/2015Vecheslav A ElaginEVPSell7,500$19.75$148,125.00View SEC Filing  
12/1/2015Richard EberlyEVPSell4,934$19.61$96,755.74View SEC Filing  
3/2/2015Marviette D JohnsonVPSell1,917$19.91$38,167.47View SEC Filing  
1/23/2015Dwight E EllingwoodDirectorBuy1,980$17.74$35,125.20View SEC Filing  
12/1/2014Susan RolihEVPSell11,219$16.46$184,664.74View SEC Filing  
11/21/2014Dwight E EllingwoodDirectorBuy1,000$16.08$16,080.00View SEC Filing  
11/18/2014John A KraeutlerCEOSell10,500$16.20$170,100.00View SEC Filing  
11/18/2014Melissa LuekeCFOSell6,713$16.20$108,750.60View SEC Filing  
11/11/2014David PhillipsDirectorBuy10,000$16.89$168,900.00View SEC Filing  
6/13/2014Robert J ReadyDirectorSell2,700$20.03$54,081.00View SEC Filing  
12/5/2013Vecheslav ElaginEVPSell4,141$23.74$98,307.34View SEC Filing  
11/22/2013Susan RolihEVPSell9,086$24.18$219,699.48View SEC Filing  
11/21/2013Richard EberlyEVPSell4,926$24.50$120,687.00View SEC Filing  
11/19/2013Lawrence BaldiniVPSell4,926$24.26$119,504.76View SEC Filing  
11/11/2013John KraeutlerCEOSell5,250$25.27$132,667.50View SEC Filing  
7/26/2013Lawrence BaldiniVPSell32,000$24.14$772,480.00View SEC Filing  
5/1/2013John A KraeutlerCEOBuy5,000$19.63$98,150.00View SEC Filing  
12/3/2012Lawrence BaldiniVPSell32,500$20.00$650,000.00View SEC Filing  
11/13/2012Robert J ReadyDirectorSell1,800$19.46$35,028.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Meridian Bioscience (NASDAQ:VIVO)
DateHeadline
capitalcube.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : September 30, 2016 (NASDAQ:VIVO)
www.capitalcube.com - September 30 at 7:12 PM
publicnow.com logoMeridian Expands Molecular Test Technology License with Eiken Chemical Co., Ltd. (NASDAQ:VIVO)
www.publicnow.com - September 26 at 8:00 PM
4-traders.com logoMeridian Bioscience : Bioline Launches New SensiFASTâ„¢ Lyo-Ready No-ROX Mix - Press Release issued by Meridian Bioscience, Inc. (NASDAQ:VIVO)
www.4-traders.com - September 23 at 7:19 PM
finance.yahoo.com logoBioline Launches New SensiFAST(TM) Lyo-Ready No-ROX Mix (NASDAQ:VIVO)
finance.yahoo.com - September 21 at 11:50 AM
publicnow.com logoBioline Launches New SensiFAST™ Lyo-Ready No-ROX Mix (NASDAQ:VIVO)
www.publicnow.com - September 21 at 11:50 AM
nasdaq.com logoVIVO Makes Bullish Cross Above Critical Moving Average (NASDAQ:VIVO)
www.nasdaq.com - September 2 at 7:47 PM
capitalcube.com logoETF’s with exposure to Meridian Bioscience, Inc. : September 2, 2016 (NASDAQ:VIVO)
www.capitalcube.com - September 2 at 7:47 PM
finanznachrichten.de logoMeridian Bioscience, Inc.: Meridian Malaria Test Wins Prestigious Innovation Award (NASDAQ:VIVO)
www.finanznachrichten.de - August 30 at 11:26 AM
4-traders.com logoMeridian Bioscience : Malaria Test Wins Prestigious Innovation Award (NASDAQ:VIVO)
www.4-traders.com - August 30 at 11:26 AM
live-pr.com logoNew Market Research Report: Meridian Bioscience, Inc. (VIVO) - Medical Equipment - Deals and Alliances Profile (NASDAQ:VIVO)
www.live-pr.com - August 25 at 8:23 PM
investors.com logoMeridian Bioscience test wins international award (NASDAQ:VIVO)
www.proactiveinvestors.com - August 25 at 8:23 PM
finance.yahoo.com logoMeridian Malaria Test Wins Prestigious Innovation Award (NASDAQ:VIVO)
finance.yahoo.com - August 25 at 8:23 PM
streetinsider.com logoMeridian Bioscience (VIVO) Announces Portfolio Expansion, First ASR Products Launch (NASDAQ:VIVO)
www.streetinsider.com - August 23 at 8:14 PM
publicnow.com logoMeridian Bioscience Expands Its Portfolio and Launches First Analyte Specific Reagent (ASR) Products (NASDAQ:VIVO)
www.publicnow.com - August 23 at 12:38 PM
finance.yahoo.com logoMERIDIAN BIOSCIENCE INC Financials (NASDAQ:VIVO)
finance.yahoo.com - August 18 at 8:21 PM
capitalcube.com logoETF’s with exposure to Meridian Bioscience, Inc. : August 16, 2016 (NASDAQ:VIVO)
www.capitalcube.com - August 16 at 8:13 PM
benzinga.com logoVIVO: Insiders vs. Shorts (NASDAQ:VIVO)
www.benzinga.com - August 15 at 8:30 PM
capitalcube.com logoMeridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q3, 2016 By the Numbers : August 12, 2016 (NASDAQ:VIVO)
www.capitalcube.com - August 12 at 8:15 PM
publicnow.com logoMagellan Diagnostics Receives CFDA Clearance for LeadCare® II in China (NASDAQ:VIVO)
www.publicnow.com - August 9 at 8:29 PM
finance.yahoo.com logoMagellan Diagnostics Receives CFDA Clearance for LeadCare II in China (NASDAQ:VIVO)
finance.yahoo.com - August 9 at 8:29 PM
capitalcube.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bearish Manner : VIVO-US : August 1, 2016 (NASDAQ:VIVO)
www.capitalcube.com - August 1 at 7:54 PM
biz.yahoo.com logoMERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Change in Directors or Pri (NASDAQ:VIVO)
biz.yahoo.com - July 29 at 1:56 PM
rttnews.com logoMeridian Bioscience Inc. Profit Falls 4% In Q3 (NASDAQ:VIVO)
www.rttnews.com - July 28 at 11:31 AM
sg.finance.yahoo.com logoMeridian Bioscience meets 3Q profit forecasts (NASDAQ:VIVO)
sg.finance.yahoo.com - July 28 at 11:04 AM
equities.com logoMeridian Bioscience Inc. (VIVO) is Trading Lower on Unusual Volume for July 05 (NASDAQ:VIVO)
www.equities.com - July 7 at 10:50 AM
capitalcube.com logoMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : July 1, 2016 (NASDAQ:VIVO)
www.capitalcube.com - July 1 at 5:26 PM
equities.com logoMeridian Bioscience Inc. (VIVO) is Trading Higher on Unusual Volume for June 29 (NASDAQ:VIVO)
www.equities.com - July 1 at 10:47 AM
capitalcube.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : June 30, 2016 (NASDAQ:VIVO)
www.capitalcube.com - June 30 at 8:21 AM
equities.com logoMeridian Bioscience Inc. (VIVO) is Trading Lower on Unusual Volume for June 21 (NASDAQ:VIVO)
www.equities.com - June 23 at 8:55 PM
publicnow.com logoMeridian Bioscience, Inc. Receives FDA Clearance for New Molecular Test for the Detection of Mycoplasma pneumoniae (NASDAQ:VIVO)
www.publicnow.com - June 15 at 8:49 AM
biz.yahoo.com logoMERIDIAN BIOSCIENCE INC Files SEC form 8-K/A, Financial Statements and Exhibits (NASDAQ:VIVO)
biz.yahoo.com - June 6 at 1:35 PM
publicnow.com logoBioline Launches New MyTaq™ Plant-PCR Kit (NASDAQ:VIVO)
www.publicnow.com - June 2 at 7:15 AM
capitalcube.com logoMeridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2016 By the Numbers (NASDAQ:VIVO)
www.capitalcube.com - May 4 at 12:17 PM
capitalcube.com logoMeridian Bioscience, Inc. :VIVO-US: Earnings Analysis: Q2, 2016 By the Numbers (NASDAQ:VIVO)
www.capitalcube.com - May 4 at 12:17 PM
biz.yahoo.com logoMERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:VIVO)
biz.yahoo.com - April 29 at 11:07 AM
biz.yahoo.com logoMERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:VIVO)
biz.yahoo.com - April 29 at 11:07 AM
thestreet.com logoMeridian Bioscience Reports Second Quarter 2016 Operating Results, Declares Regular Cash Dividend, And Reaffirms Fiscal 2016 Guidance (NASDAQ:VIVO)
www.thestreet.com - April 28 at 8:31 AM
publicnow.com logoMeridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae (NASDAQ:VIVO)
www.publicnow.com - April 27 at 7:21 AM
publicnow.com logoMeridian Bioscience Launches New Molecular Test for the Detection of Mycoplasma pneumoniae (NASDAQ:VIVO)
www.publicnow.com - April 27 at 7:21 AM
capitalcube.com logoMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : April 26, 2016 (NASDAQ:VIVO)
www.capitalcube.com - April 26 at 12:46 PM
capitalcube.com logoMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : April 26, 2016 (NASDAQ:VIVO)
www.capitalcube.com - April 26 at 12:46 PM
capitalcube.com logoETF’s with exposure to Meridian Bioscience, Inc. : April 26, 2016 (NASDAQ:VIVO)
www.capitalcube.com - April 26 at 12:14 PM
capitalcube.com logoETF’s with exposure to Meridian Bioscience, Inc. : April 26, 2016 (NASDAQ:VIVO)
www.capitalcube.com - April 26 at 12:14 PM
capitalcube.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : April 25, 2016 (NASDAQ:VIVO)
www.capitalcube.com - April 25 at 8:12 AM
capitalcube.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : April 25, 2016 (NASDAQ:VIVO)
www.capitalcube.com - April 25 at 8:12 AM
capitalcube.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : March 29, 2016 (NASDAQ:VIVO)
www.capitalcube.com - March 29 at 8:05 AM
capitalcube.com logoMeridian Bioscience, Inc. breached its 50 day moving average in a Bullish Manner : VIVO-US : March 29, 2016 (NASDAQ:VIVO)
www.capitalcube.com - March 29 at 8:05 AM
feeds.reuters.com logoBRIEF-Meridian Bioscience says bought Magellan Diagnostics for $66 mln (NASDAQ:VIVO)
feeds.reuters.com - March 24 at 5:26 PM
capitalcube.com logoMeridian Bioscience, Inc. – Value Analysis (NASDAQ:VIVO) : February 9, 2016 (NASDAQ:VIVO)
www.capitalcube.com - February 9 at 2:51 PM
biz.yahoo.com logoMERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report (NASDAQ:VIVO)
biz.yahoo.com - February 9 at 8:57 AM

Social

Meridian Bioscience (NASDAQ:VIVO) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff